

KURZPROTOKOLL
BGBC003

Öffentlicher Titel	Phase I/II Studie zu BGB324, Cytarabin und Decitabin bei Patienten mit AML und MDS
Wissenschaftl. Titel	A Phase Ib/II Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine or Decitabine in Patients With Acute Myeloid Leukemia or as a Single Agent in Patients With Myelodysplastic Syndrome
Kurztitel	BGBC003
Studienart	prospektiv, Therapiestudie, offen/unverblindet, Pharma-Studie, mehrarmig
Studienphase	Phase I/II
Erkrankung	Blut: Myeloische Neoplasien/Dysplasien: Myelodysplastische Syndrome (MDS) Blut: Akute myeloische Leukämie (AML): Neu diagnostiziert / de novo Blut: Akute myeloische Leukämie (AML): Rezidiert/refraktär
Einschlusskriterien	- Provision of signed written informed consent - Histological, molecular or cytological confirmation of: (I.) AML (with the exception of AML M3), patients with relapsed or refractory AML following treatment with cytotoxic chemotherapy or a targeted or biologic agent; (II.) high risk group MDS, according to IPSS Risk Stratification (Norway Only) - Histological, molecular or cytological confirmation of: (I.) AML (with the exception of AML M3); (II.) AML unsuitable for intensive chemotherapy; (III.) newly diagnosed AML unsuitable for intensive chemotherapy; (IV.) MDS: a.) high/intermediate (int-2) risk group MDS, according to IPSS Risk Stratification (Norway Only); b.) patients with previously treated MDS (with the exception of deletion 5q MDS) (US only) - Age 18 years or older - Female patients of childbearing potential must have a negative serum pregnancy test within 3 days prior to taking their first dose of BGB324. Male patients and female patients of reproductive potential must practice highly methods of contraception throughout the study and for => 3 months after the last dose of BGB324. - Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
Ausschlusskriterien	- Patients who have a matched donor and are candidates for allogeneic bone marrow transplantation - Pregnant or lactating - Abnormal left ventricular ejection fraction (less than the lower limit of normal for a patient of that age at the treating institution or <45%, whichever is lower). - Congestive cardiac failure of >Grade 2 severity according to the NYHA defined as symptomatic at less than ordinary levels of activity - Unstable cardiac disease, including unstable angina or unstable hypertension, or need to change medication within 6 weeks of provision of consent due to lack of disease control - Ischemic cardiac event including myocardial infarction within 3 months prior to first dose - Current treatment with any agent known to cause Torsades de Pointes which cannot be discontinued at least five half-lives or two weeks prior to the first dose of study treatment. - Treatment with any of the following; histamine receptor 2 inhibitors, proton pump inhibitors or antacids within 3 days or 5 half-lives of administration of BGB234, whichever is longer. - Radiotherapy or chemotherapy within the 14 days prior to the first dose of BGB324 being administered (other than hydroxyurea) - Active, uncontrolled central nervous system (CNS) disease including CNS leukemia - Major surgery within 28 days prior to the start of BGB324 - excluding skin biopsies and procedures for insertion of central venous access devices - Prior exposure to Astellas ASP2215.

KURZPROTOKOLL
BGBC003

- Unresolved CTCAE >Grade 2 toxicity (other than stable toxicity) from previous anti-cancer therapy excluding alopecia.

Alter	18 Jahre und älter
Prüfzentren	Universitätsmedizin Frankfurt (Geschlossen) Medizinische Klinik II, Hämatologie/Onkologie Theodor-Stern-Kai 7 60590 Frankfurt am Main Silvia Koss Tel: 069 6301-80429 Fax: 069 6301-83655 silvia.koss@unimedizin-ffm.de
Sponsor	BerGenBio AS (Hauptsponsor)
Förderer	BerGenBio AS
Registrierung in anderen Studienregistern	ClinicalTrials.gov NCT02488408 EudraCT 2014-000165-46
Links	Studiendokumente zum Download (roXtra)